Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

ERC Advanced Grant for Andreas Trumpp

No. 26 | 26/04/2022 | by Koh

With its "Advanced Grants", the European Research Council ERC supports visionary projects in basic research. This year, the Council awarded cancer researcher Andreas Trumpp, Division Head at the German Cancer Research Center (DKFZ) and Director of HI-STEM* gGmbH, with the prestigious research grant.

Andreas Trumpp
© Anspach/DKFZ

The European Research Council promotes basic research in order to advance particularly forward-looking projects and open up new interdisciplinary areas of knowledge. For outstanding, already established researchers in Europe, the Council annually announces the "ERC Advanced Grants", which are awarded in a highly competitive procedure.

Some types of cancer, which grow particularly aggressively and develop therapy resistance particularly early and frequently, are characterized by extreme damage to the genetic material. These include lung cancer, glioblastoma, metastases from various cancers, and the most aggressive form of acute myeloid leukemia, known as "AML with complex karyotype" (CK-AML).

Chromosomal damages are complex: entire sections of genetic material are missing, others are duplicated, inverted, or completely reassembled. They can affect a single chromosome or the entire set of chromosomes. Researchers can hardly understand how cells with such puzzled-together sets of genetic material can be viable at all. It is poorly understood what mechanisms these cancer cells use to divide almost indefinitely while developing resistance to currently available therapies.

Using CK-AML as an example, Andreas Trumpp wants to get to the bottom of this mystery and investigate the molecular evolution of tumor cells at the single cell level over the time course of the disease: at the time of diagnosis, immediately after therapy, and at relapse.

For this purpose, Trumpp and colleagues use newly developed analytical methods that not only reveal the structural genetic variations, but also the resulting consequences on the molecular networks of cell control. The analyses are performed at the highest resolution down to the level of single cells. In this way, Trumpp and his team hope to understand which disruptions in the signaling networks confer dangerous stem cell properties on blood cancer cells, induce therapy resistance, or enable them to escape the immune system.

The knowledge gained from the analyses of cancer cells from affected individuals will then serve as the basis for developing new strategies to combat highly aggressive tumor cells by combining pharmacological and immunotherapeutic approaches. The new strategies will then be tested in mice to which human leukemia cells have been transferred. Successful treatment concepts will ultimately serve as the basis for new clinical trials.

With the project called "SHATTER-AML", Trumpp wants to better understand which evolutionary processes occur in cancers characterized by structural genetic defects under the pressure of therapy. The results obtained from the example of CK-AML will also expand the understanding of other aggressive cancers that are also based on extensive chromosomal alterations. The goal of the scientists in Trumpp's laboratory is to develop more effective immunological and precision oncology therapies for these cancers, for which treatment options are often inadequate today.

* The Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) gGmbH was founded in 2008 as a public-private partnership by the DKFZ and the Dietmar Hopp Foundation

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS